BioSpace News Archive

Pictured: Bristol Myers Squibb office in California

Lymphoma

BMS Positions Breyanzi for Another Indication as LOE Woes Mount

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the coming years.

February 10, 2025

·

2 min read

·

Tristan Manalac

scientist in microbiology laboratory working with E coli culture

Infectious disease

AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.

February 10, 2025

·

2 min read

·

Dan Samorodnitsky

Press Releases

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

February 10, 2025

·

7 min read

Press Releases

IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress

February 10, 2025

·

2 min read

External view of Boehringer Ingelheim's headquarters in Silicon Valley

Drug Development

Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary fibrosis—nearly six months after achieving a similar feat in idiopathic pulmonary fibrosis. Boehringer plans to submit for FDA and other global approvals in both indications.

February 10, 2025

·

2 min read

·

Heather McKenzie

Press Releases

Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

February 10, 2025

·

5 min read

Press Releases

Next Generation Sequencing Market Size Soars by 21.74% CAGR to Reach $73.47 Billion by 2034